Acuitas Therapeutics

Vancouver, BC
Reagent / Material Supplier
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (11) ○ EMA GMP ○ MHRA GMP

Quick Facts: Acuitas Therapeutics

Signal Score
59.0/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Vancouver, BC
Modalities
mRNA
Active Programs
No ClinicalTrials.gov matches confirmed — 6 partnership announcements in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Acuitas Therapeutics

Reagent/raw material supplier.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 6 partnership announcements found in press monitoring.
Programs no verified data
Sponsorsno verified data
ModalitiesmRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
Strong partnership activity (6 articles)
Sites: Vancouver, BC
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press11 articles
Strong partnership activity (6 articles)

Recent News 11 articles

partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com Nigeria
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com Nigeria
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com South Africa
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com South Africa
partnership 2026-04-20
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy - TipRanks
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy  TipRanks
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech - Investing.com
Genflow partners with Acuitas for gene therapy delivery tech  Investing.com
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com Australia
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com Australia
partnership 2026-04-20
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com - Investing.com UK
Genflow partners with Acuitas for gene therapy delivery tech By Investing.com  Investing.com UK
general 2026-04-16
Circio and Acuitas partner on circular RNA CAR T therapy - Drug Target Review
Circio and Acuitas partner on circular RNA CAR T therapy  Drug Target Review
general 2026-04-15
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics - TradingView — Track All Markets
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics  TradingView
general 2026-04-15
Circio, Acuitas Therapeutics to Evaluate In-vivo CAR-T Cell Therapy Technology - marketscreener.com
Circio, Acuitas Therapeutics to Evaluate In-vivo CAR-T Cell Therapy Technology  marketscreener.com
general 2026-04-15
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics - Finansavisen
Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics  Finansavisen
general 2026-04-15
Circio Holding ASA And Acuitas Therapeutics Enter In Vivo Car-T Cell Therapy Evaluation Agreement - marketscreener.com
Circio Holding ASA And Acuitas Therapeutics Enter In Vivo Car-T Cell Therapy Evaluation Agreement  marketscreener.com
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

Evonik Health Care
Birmingham, AL · Vancouver, BC
Signal Score: 81.5
mRNA, Biologics
Precision NanoSystems (Cytiva)
Vancouver, BC
Signal Score: 69.0
mRNA
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Aldevron
Fargo, ND
Signal Score: 85.3
Plasmid, mRNA